Lupin Gains FDA Nod for Generic Urea Cycle Disorder Treatment
Event summary
- Lupin received FDA approval for its generic version of Glycerol Phenylbutyrate Oral Liquid, bioequivalent to Horizon Therapeutics' Ravicti.
- The drug is indicated for chronic management of urea cycle disorders (UCDs).
- Ravicti had $337 million in sales for the year ended December 2025 (IQVIA MAT DEC 2025).
- Lupin is a global pharmaceutical leader with operations in over 100 markets.
The big picture
Lupin's FDA approval for Glycerol Phenylbutyrate Oral Liquid marks a strategic entry into the specialized UCD treatment market, challenging Horizon Therapeutics' dominance. This move aligns with Lupin's broader strategy of expanding its complex generics portfolio, leveraging its global manufacturing and R&D capabilities. The $337 million sales figure for the reference drug underscores the significant market opportunity.
What we're watching
- Market Share Shift
- How Lupin's entry will affect Horizon Therapeutics' market share in the UCD treatment space.
- Pricing Dynamics
- Whether Lupin can sustain competitive pricing while maintaining profitability.
- Regulatory Compliance
- The pace at which Lupin can navigate potential regulatory hurdles in other markets.
Related topics